

HC SURGICAL SPECIALISTS LIMITED

(the “**Company**”)
(Incorporated in the Republic of Singapore)
(Company Registration No. 201533429G)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that the Annual General Meeting of the Company will be held at 5 Stevens Road, Raffles Room, Level 2 – Main Clubhouse, Tanglin Club, Singapore 257814 on Tuesday, 29 September 2026 at 2.00 p.m. to transact the following businesses:

AS ORDINARY BUSINESS

1. To lay before the meeting the Audited Financial Statements of the Company for the financial year ended 31 May 2026 and the Directors’ Statement and the Auditor’s Report thereon.
(Please see explanatory note 1)
2. To re-elect the following Directors who are retiring in accordance with the provisions of the Company’s Constitution:-
 - (a) Dr. Chia Kok Hoong (pursuant to Regulation 97)
(Resolution 1)
(Please see explanatory note 2)
 - (b) Mr. Chong Weng Hoe (pursuant to Regulation 97)
(Resolution 2)
(Please see explanatory note 3)
3. To approve the payment of Directors’ fees of \$129,250/- for the financial year ended 31 May 2026. (FY2025: \$122,000/-)
(Resolution 3)
4. To declare a final dividend (tax-exempt one-tier) of \$0.0118 per ordinary share for the financial year ended 31 May 2026. (FY2025: \$0.0118 per ordinary share)
(Resolution 4)
5. To re-appoint Messrs BDO LLP as auditors of the Company and to authorise the Directors to fix their remuneration.
(Resolution 5)

AS SPECIAL BUSINESS

To consider and, if thought fit, to pass the following ordinary resolutions with or without modifications:-

6. Authority to allot and issue ordinary shares

“That, pursuant to Section 161 of the Companies Act 1967 (“**Companies Act**”), and Rule 806 of the Singapore Exchange Securities Trading Limited (“**Exchange**”) Listing Manual Section B: Rules of Catalyst (“**Catalist Rules**”), approval be and is hereby given to the Directors of the Company at any time to such persons and upon such terms and for such purposes as the Directors of the Company may in their absolute discretion deem fit, to:

 - (a) issue shares in the capital of the Company whether by way of rights, bonus or otherwise;
 - (b) make or grant offers, agreements or options that might or would require shares to be issued or other transferable rights to subscribe for or purchase shares (collectively, “**Instruments**”) including but not limited to the creation and issue of options, warrants, debentures or other instruments convertible into shares;
 - (c) issue additional Instruments arising from adjustments made to the number of Instruments previously issued in the event of rights, bonus or capitalisation issues; and

- (d) (Notwithstanding the authority conferred by the Shareholders may have ceased to be in force) issue shares in pursuance of any Instrument made or granted by the Directors while the authority was in force, provided always that:
- (i) the aggregate number of shares to be issued pursuant to this resolution (including shares to be issued in pursuance of Instruments made or granted pursuant to this resolution) does not exceed one hundred per cent (100%) of the total number of issued shares excluding treasury shares and subsidiary holdings of the Company, of which the aggregate number of shares (including shares to be issued in pursuance of Instruments made or granted pursuant to this resolution) to be issued other than on a *pro-rata* basis to Shareholders of the Company does not exceed fifty percent (50%) of the total number of issued shares excluding treasury shares and subsidiary holdings of the Company, and (subject to such manner of calculation as may be prescribed by the Exchange for the purpose of determining the aggregate number of shares that may be issued under this paragraph) for the purpose of this resolution, the issued share capital shall be the Company's total number of issued shares excluding treasury shares and subsidiary holdings at the time this resolution is passed, after adjusting for:
 - (a) new shares arising from the conversion or exercise of convertible securities, or
 - (b) new shares arising from exercising share options or vesting of share awards outstanding or subsisting at the time this resolution is passed provided the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules, and
 - (c) any subsequent bonus issue, consolidation or subdivision of the Company's shares;
 - (ii) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the Exchange) and the Constitution for the time being of the Company; and
 - (iii) such authority shall, unless revoked or varied by the Company at a general meeting, continue in force until the conclusion of the next annual general meeting ("AGM") or the date by which the next AGM of the Company is required by law to be held, whichever is the earlier." **(Resolution 6)**
(Please see explanatory note 4)

7. The Proposed Renewal of the Share Buy-Back Mandate

"That:

- (a) for the purposes of the Catalist Rules and the Companies Act, the Directors of the Company be and are hereby authorised to exercise all the powers of the Company to purchase or acquire its issued and fully paid-up shares not exceeding in aggregate the Maximum Limit (as defined below), at such price(s) as may be determined by the Directors or a committee of Directors that may be constituted for the purposes of effecting purchases or acquisitions of shares by the Company from time to time up to the Maximum Price (as defined below), whether by way of:
 - (i) a market purchase ("**Market Purchase**"), transacted on the Exchange through the ready market, and which may be transacted through one or more duly licensed stockbrokers appointed by the Company for the purpose: and/or
 - (ii) an off-market purchase ("**Off-Market Purchase**"), effected otherwise than on the Exchange pursuant to an equal access scheme in accordance with Section 76C of the Companies Act, and otherwise in accordance with all other laws and regulations, including but not limited to, the provisions of the Companies Act and the Catalist Rules as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the "**Share Buy-Back Mandate**");

- (b) unless varied or revoked by the Shareholders in a general meeting, purchases or acquisitions of shares pursuant to the Share Buy-Back Mandate may be made, at any time and from time to time during the period commencing from the date of the passing of this Resolution and expiring on the earliest of:
- (i) the date the next AGM is held, or is required by law to be held;
 - (ii) the date on which the Share buy-backs are carried out to the full extent mandated; or
 - (iii) the date on which the authority conferred in the Share Buy-Back Mandate is varied or revoked by the Shareholders in a general meeting

(the “**Relevant Period**”).

- (c) in this Resolution:

“**Maximum Limit**” means that number of shares of the Company representing not more than ten per cent (10%) of the total number of issued shares of the Company (excluding treasury shares and subsidiary holdings) as at the date of the passing of this Resolution, unless the Company has effected a reduction of the share capital of the Company with the applicable provisions of the Companies Act at any time during the Relevant Period, in which event the total number of issued Shares shall be taken to be the total number of issued shares of the Company as altered (excluding any treasury shares that may be held by the Company from time to time and subsidiary holdings);

“**Maximum Price**”, in relation to a share to be purchased or acquired, means the purchase price (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) as determined by the Directors, shall not exceed:

- (i) in the case of a Market Purchase, one hundred and five per cent (105%) of the Average Closing Price (as defined below); and
- (ii) in the case of an Off-Market Purchase pursuant to an equal access scheme, one hundred and twenty per cent (120%) of the Average Closing Price, where:

“**Average Closing Price**” means the average of the closing market prices of the shares of the Company over the last five (5) Market Days, on which transactions in the shares were recorded, before the day on which the purchase or acquisition of shares was made, or as the case may be, before the day of the making of the offer pursuant to the Off-Market Purchase, and deemed to be adjusted for any corporate action that occurs during the relevant five (5) Market Days period and the day on which the purchases are made;

“**day of the making of the offer**” means the day on which the Company announces its intention to make an offer for an Off-Market Purchase, stating therein the purchase price (which shall not be more than the Maximum Price for an Off-Market Purchase calculated on the foregoing basis) for each share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase; and

“**Market Day**” means a day on which the Exchange is open for trading in securities; and

- (d) the Directors and/or any of them be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) as they and/or he may consider necessary, expedient, incidental or in the interests of the Company to give effect to the transactions contemplated and/or authorised by this Resolution.”

(Resolution 7)

(Please see explanatory note 5)

8. The Proposed Adoption of the 2026 HCSS Employee Share Option Scheme (the “**2026 HCSS ESOS**”)

“That the employee share option scheme to be known as the 2026 HCSS Employee Share Option Scheme, the details and particulars of which have been set out in the Appendix, be and is hereby approved and adopted substantially in the form set out in the Rules of the 2026 HCSS ESOS, and the Share Option Scheme Administration Committee and/or Directors of the Company be and are hereby authorised:

- (a) to establish and administer the 2026 HCSS ESOS;
- (b) to modify and/or amend the 2026 HCSS ESOS from time to time provided that such modifications and/or amendments are effected in accordance with the provisions of the 2026 HCSS ESOS and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the 2026 HCSS ESOS; and
- (c) offer and grant option(s) in accordance with the Rules of the 2026 HCSS ESOS and pursuant to Section 161 of the Companies Act 1967, to allot and issue from time to time such number of fully paid-up new shares or deliver or transfer such number of treasury shares as may be required to be issued or transferred pursuant to the exercise of the Option(s) under the 2026 HCSS ESOS, provided always that the aggregate number of new shares to be issued or issuable pursuant to the 2026 HCSS ESOS and in respect of all other share-based incentive schemes of the Company shall not exceed 15.0% of the issued shares of the Company from time to time (excluding treasury shares and subsidiary holdings).”

(Resolution 8)

(Please see explanatory note 6)

9. To approve the offer and grant of option(s) at a discount

“That subject to and contingent upon the passing of Ordinary Resolution 8, the Share Option Scheme Administration Committee and/or Directors of the Company be and are hereby authorised to offer and grant option(s) in accordance with the Rules of the 2026 HCSS ESOS with the exercise price set at a discount to the market price, provided that such discount does not exceed 20.0% of the market price of a share, or such other percentage or amount as may be determined in accordance with the Rules of the 2026 HCSS ESOS, provided that such discount does not exceed the relevant limits set by the Exchange from time to time.”

(Resolution 9)

(Please see explanatory note 6)

10. The Proposed Adoption of the 2026 HCSS Performance Share Plan (the “**2026 HCSS PSP**”).

“That the performance share plan to be known as the 2026 HCSS Performance Share Plan, the details and particulars of which have been set out in the Appendix, be and is hereby approved and adopted substantially in the form set out in the Rules of the 2026 HCSS PSP, and the Performance Share Plan Committee and/or Directors of the Company be and are hereby authorised:

- (a) to establish and administer the 2026 HCSS PSP;
- (b) to modify and/or amend the 2026 HCSS PSP from time to time provided that such modifications and/or amendments are effected in accordance with the provisions of the 2026 HCSS PSP and to do all such acts and to enter into all such transactions, arrangements and agreements as may be necessary or expedient in order to give full effect to the 2026 HCSS PSP; and

- (c) to grant award(s) in accordance with the Rules of the 2026 HCSS PSP and pursuant to Section 161 of the Companies Act 1967, to allot and issue from time to time such number of fully paid-up new shares or deliver or transfer such number of treasury shares as may be required to be issued or delivered pursuant to the vesting and release of award(s) under the 2026 HCSS PSP, provided always that the aggregate number of new shares to be issued or issuable pursuant to the 2026 HCSS PSP and in respect of all other share-based incentive schemes of the Company shall not exceed 15.0% of the issued shares of the Company from time to time (excluding treasury shares and subsidiary holdings)."

(Resolution 10)

(Please see explanatory note 6)

BY ORDER OF THE BOARD

Lin Moi Heyang
Company Secretary

Singapore, 14 September 2026

Explanatory Notes:-

1. This Agenda is meant for discussion only as under the provisions of Section 201 of the Companies Act and Regulation 142 of the Company's Constitution, the Audited Financial Statements need to be laid before the meeting and hence, the matter will not be put forward for voting.
2. The key information of Dr. Chia Kok Hoong can be found on page 13 in the Annual Report. Dr. Chia Kok Hoong will, upon re-election as a Director of the Company, remain as the Executive Director and Medical Director.
3. The key information of Mr. Chong Weng Hoe can be found on page 14 in the Annual Report. Mr. Chong Weng Hoe will, upon re-election as a Non-Independent Non-Executive Director of the Company, remain as a member of the Audit and Risk Management Committee, Remuneration Committee and Nominating Committee of the Company. Mr. Chong Weng Hoe is not considered independent for the purpose of Rule 704(7) of the Catalist Rules.
4. The ordinary resolution 6 above is to authorise the Directors of the Company from the date of the above AGM until the next AGM to issue shares and convertible securities in the Company up to an amount not exceeding in aggregate one hundred per cent (100%) of the issued share capital of the Company of which the total number of shares and convertible securities issued other than on a *pro-rata* basis to existing Shareholders shall not exceed fifty per cent (50%) of the issued share capital of the Company (excluding treasury shares and subsidiary holdings) at the time the resolution is passed, for such purposes as they consider would be in the interests of the Company. This authority will, unless revoked or varied at a general meeting, expire at the next AGM of the Company.
5. The ordinary resolution 7 above is to authorise the Directors of the Company from the date of the above AGM until the date of the next AGM, or the date by which the next AGM of the Company is required by law to be held, or the date on which the share buy-backs are carried out to the full extent mandated, or the date on which such authority is revoked or varied by the Shareholders in a general meeting, whichever is the earliest, to purchase up to ten per cent (10%) of the total number of issued shares in the capital of the Company (excluding treasury shares and subsidiary holdings). Please refer to the Appendix to this Annual Report for details.
6. The ordinary resolutions 8, 9 and 10, if passed, will empower the Directors and/or the relevant committee(s) to establish and administer the 2026 HCSS Employee Share Option Scheme and the 2026 HCSS Performance Share Plan, to modify and/or amend the same from time to time in accordance with their respective provisions, and to do all such acts and enter into all such transactions, arrangements and agreements as may be necessary or expedient to give full effect thereto, including the grant of options and allotment and issue of shares pursuant to the exercise of options under the 2026 HCSS Employee Share Option Scheme, as well as the grant of awards and the allotment and issue of shares pursuant to the vesting of awards under the 2026 HCSS Performance Share Plan, provided that the aggregate number of shares to be issued shall not exceed fifteen per cent (15%) of the Company's issued shares, excluding treasury shares, in the capital of the Company from time to time.

Documents for the AGM

1. Printed copies of this Notice of AGM, the Proxy Form and the Request Form for members to request for a printed copy of the Annual Report and Appendix will be sent to all members. Printed copies of the Annual Report and Appendix will not be sent to members. Members may request for printed copies of the Annual Report and Appendix by completing and returning the Request Form to the Company by 23 September 2026. These documents have also been made available on SGXNet as well as the Company's website at the following URLs:-

SGX's website: <https://www.sgx.com/securities/company-announcements>

Company's website: <https://www.hcsurgicalspecialists.com/en/investor-relation/news>

Submission of questions prior to the AGM

2. Members may submit questions relating to the resolutions to be tabled for approval at the AGM in advance of the AGM. Such questions must be submitted by 21 September 2026, being seven (7) calendar days from the publication of this Notice of AGM in the following manner:
 - (a) if submitted electronically, by email to contact@hcsurgicalspecialists.com; or
 - (b) if submitted in hard copy, by post to the Company's office at 233 River Valley Road, #B1-04/05 RV Point, Singapore 238291.

Members who submit questions must provide the following information for authentication: (i) member's full name; (ii) member's identification number / registration number; (iii) member's address; and (iv) the manner in which the member holds shares in the Company (e.g., via CDP, scrip, CPF or SRS), failing which the Company shall be entitled to regard the submission as invalid and not respond to the questions submitted.

All questions submitted in advance of the AGM must be received by the Company by the date stated above to be treated as valid.

3. The Company shall address relevant and substantial questions (as may be determined by the Company in its sole discretion) received prior to the AGM via SGXNet and on its corporate website by 23 September 2026. The Company will publish the minutes of the AGM on SGXNet and the Company's website within one month after the date of the AGM.

Voting by Proxy

4.
 - (a) A member who is not a relevant intermediary is entitled to appoint not more than two proxies to attend, speak and vote at the AGM. Where a member appoints more than one proxy, the proportion of the shareholding concerned to be represented by each proxy shall be specified in the Proxy Form.
 - (b) A member who is a relevant intermediary is entitled to appoint more than two proxies to attend, speak and vote at the AGM, but such proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member appoints more than two proxies, the number and class of shares in relation to which each proxy has been appointed shall be specified in the Proxy Form.

"Relevant intermediary" has the meaning given to it in Section 181 of the Companies Act.

5. A proxy need not be a member of the Company.
6. The duly executed Proxy Form can be submitted to the Company in the following manner:
 - (a) if submitted in hard copy by post, be lodged at the office of the Company's Share Registrar at 9 Raffles Place, #26-01, Republic Plaza, Singapore 048619; or
 - (b) if submitted electronically, by sending a scanned PDF copy via email to sg.is.proxy@vistra.com,

in either case, by **2.00 p.m.** on **26 September 2026** (being at least 72 hours before the time appointed for holding the AGM) (the "**Proxy Deadline**").

7. A member who wishes to submit a Proxy Form must download, complete and sign the Proxy Form, before submitting it by post to the address provided above, or by scanning and sending it electronically to the email address provided above.

8. Investors who hold their Shares through relevant intermediaries as defined in Section 181 of the Companies Act (including CPF investors, SRS investors and holders under depository agents) and who wish to exercise their votes should approach their respective relevant intermediaries (including their respective CPF agent banks, SRS approved banks or depository agents) to submit their votes at least 7 working days before the AGM. CPF/SRS Investors should contact their respective CPF Agent Banks or SRS Operators for any queries they may have with regard to the appointment of proxy for the AGM.
9. The Company shall be entitled to reject the instrument appointing a proxy or proxies if it is incomplete, improperly completed, illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument. Where the Chairman of the AGM is appointed as proxy and in the absence of specific directions as to voting, the Chairman will be able to vote at his discretion.

Personal data privacy:

By (a) submitting an instrument appointing a proxy(ies) to attend, speak and vote at the AGM and/or any adjournment thereof, or (b) submitting any question prior to the AGM in accordance with this Notice of AGM, a member of the Company (i) consents to the collection, use and disclosure of the member's personal data by the Company (or its agents or service providers) for the purposes of processing and administration by the Company (or its agents or service providers) of proxy(ies) appointed for the AGM (including any adjournment thereof), and the preparation and compilation of the attendance lists, minutes and other documents relating to the AGM (including any adjournment thereof), and in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (the "**Purposes**"), (ii) warrants that where the member discloses the personal data of the member's proxy(ies) to the Company (or its agents or service providers), the member has obtained the prior consent of such proxy(ies) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) for the Purposes; and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.

SPECIAL NOTE IF YOU ARE ATTENDING THE AGM:

Dress code

All members and/or their appointed proxy(ies) are required to be presentably dressed at all times. NO shorts, slippers, t-shirts, and jeans are allowed.

Parking

Parking is available along the roadside (parallel parking lots) or nearby malls.

Conduct

1. Mobile phones must be put on silent mode.
2. Smoking is prohibited in all air-conditioned areas.
3. Boisterous or unseemly behaviour is not permitted.

The Company sincerely seeks your cooperation to observe the relevant Rules and Byelaws of The Tanglin Club.

*This Notice of AGM has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this Notice of AGM, including the correctness of any of the statements or opinions made, or reports contained in this Notice of AGM.*

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.